Document is current
Any future updates will be listed below
-
Authors
Lindsø Andersen, P. https://orcid.org/0000-0002-0132-4715
Jemec, G. B. https://orcid.org/0000-0002-0712-2540
Erikstrup, C. https://orcid.org/0000-0001-6551-6647
Didriksen, M. https://orcid.org/0000-0002-4856-496X
Dinh, K. M. https://orcid.org/0000-0003-1881-5673
Mikkelsen, S. https://orcid.org/0000-0001-7806-1143
Sørensen, E.
,
Nielsen, K. R.
Bruun, M. T. https://orcid.org/0000-0002-8819-5388
Hjalgrim, H. https://orcid.org/0000-0002-4436-6798
Hansen, T. F. https://orcid.org/0000-0001-6703-7762
Sækmose, S. G. https://orcid.org/0000-0002-1346-0052
Ostrowski, S. R. https://orcid.org/0000-0001-5288-3851
Saunte, D. M. L. https://orcid.org/0000-0003-2312-5976
Pedersen, O. B. https://orcid.org/0000-0001-7953-1047
-
Funding
Funding for this research was provided by:
LEO Fondet (LF18002, LF18002, LF18002, LF18002)
Naestved, Slagelse and Ringsted Hospitals’ Research Fund
- License Information
-
More Information
Article History
Received: 8 August 2022
Revised: 10 October 2022
Accepted: 31 October 2022
First Online: 17 November 2022
Declarations
:
: PLA received support from Naestved, Slagelse, and Ringsted Hospitals’ Research Fund and a PhD grant from LEO Foundation (grant no.: LF18002). DMS reports grants and personal fees from Leo Pharma, Janssen, and Novartis outside the submitted work. GBJ reports grants from Leo research foundation, during the conduct of the study, personal fees from Coloplast, Chemocentryx, Leo Pharma, Incyte, Kymera, and VielaBio, grants and personal fees from Novartis, grants and personal fees from UCB, grants and personal fees from Inflarx, AbbVie, Novartis, and UCB, grants from Leo Foundation, Afyx, Jansen-Cilag, CSL Bering, Regeneron, and Sanofi outside the submitted work. TFH, MTB, KRN, KMD, CE, SGS, SRO, ES, MD, SM, HH, and OBP have no conflicts of interests to disclose.
